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Abstract Öz 
Purpose: We aimed to investigate erythrocyte 
alloimmunization frequency and related factors in our 
region where SCD is common. 
Material and Methods: This study was planned as a 
single center, cross-sectional and retrospective cohort 
study. A total of 216 patients who had been followed up 
due to SCD [Hemoglobin (Hb) SS, Hb S-β thalassemia, 
Hb S-α thalassemia] were included in this study. Patients 
were divided to two groups according to amount of 
transfusion. The patients who had received less than 6 
transfusions per year and who did not have the history of 
erythropheresis were allocated to Group 1, and the 
patients who had received 6 or more simple transfusion 
per year or who had undergone erythrocyte exchange were 
allocated to Group 2. 
Results: Of 216 SCD patients included in the study. 
Alloimmunization was detected in 67 (31.0%) out of 216 
patients who underwent transfusion, and in 17 (30.4%) out 
of 56 patients in Group 1 and in 50 (31.3%) out of 160 
patients in Group 2. When the patients were analyzed 
according to alloimmunization development, our study 
revealed that neither SCD complications are a risk factor 
for alloimmunization nor alloimmunization increases 
mortality rates.  
Conclusion: High alloimmunization frequency found in 
our study suggests the insufficient adherence of 
alloimmunization-prevention policies in RBC transfusions 
performed except experienced institutions. Therefore 
alloimmunization may be reduced or prevented through 
performing extended red cell typing among SCD patients.  
Amaç: Orak hücre hastalığının sık görüldüğü bölgemizde 
eritrosit alloimmmünizasyon sıklığını ve ilişkili durumları 
araştırmayı amaçladık. 
Gereç ve Yöntem: bu çalışma tek merkezli, zamansal 
kesitli ve geriye dönük kohort çalşıması olarak 
planlanmıştır.  Toplamda 216 orak hücre hastalığı 
[Hemoglobin (Hb) SS, Hb S-β talasemi, Hb S-α talasemi] 
tanısı olan hasta çalışmaya dahil edilmiştir. Hastalar 
transfüzyon miktarına gore iki gruba ayrılmıştır. Yılda 
6’dan daha az transfüzyon alan ya da eritroferez öyküsü 
olmayan hastalar Grup 1’e, yılda 6 ve daha fazla basit 
transfüzyon alan ya da eritroferez işlemine alınan hastalar 
Grup 2’ye dahil edilmiştir. 
Bulgular: Çalışmamıza 216 hasta dahil edilmiştir. 
Transfüzyon tedavisi alan toplam 216 hastanın 67 
(%31.0)’sinde, Grup 1’deki 56 hastanın 17’sinde (%30.4), 
Grup 2’deki 160 hastanın 50’sinde (%31.3) tespit 
edilmiştir. Hastalar alloimmünizasyon gelişimi açısından 
analiz edildiğinde, çalışmamız ne orak hücre 
komplikasyonlarının alloimmünizasyon gelişimi için ne de 
alloimmünizasyonun ölüm için bir risk faktörü olmadığını 
göstermiştir. 
Sonuç: Çalışmamamızda bulunan yüksek 
alloimmünizasyon sıklığı, tecrübeli merkezler dışında 
yapılan transfüzyonlarda alloimmünizasyonu önleyici 
politikalara yeteri kadar uyulmadığı konusunda fikir 
vermektedir. Bu nedenle orak hücre anemili hastalarda 
alloimmünizasyon, ayrıntılı eritrosit antijen tanımlama 
işlemi yapılarak azaltılabilir veya önlenebilir.  
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INTRODUCTION 
Red blood cell (RBC) transfusion therapy is an 
important management strategy in sickle cell disease 
(SCD) for several acute and chronic indications1. 
Despite improved patient outcomes with 
hydroxyurea administration, indications for chronic 
transfusions have increased in the last 10 years and 
are associated with considerable reduction in 
morbidity and mortality2. However, 
alloimmunization to RBC blood group antigens 
remains a major complication for patients with SCD 
and often presents significant challenges in their 
medical management3. Alloimmune reactions can be 
associated with significant morbidity in SCD, 
including delay in urgent treatment of stroke and 
acute chest syndrome due to difficulty to find 
compatible blood, delayed transfusion reactions, 
hyperhemolysis, and autoantibody formation4. 
The incidence of alloimmunization in patients with 
SCD ranges from 7% to 47%, depending on age, 
RBC exposures, and extent of antigen matching for 
blood groups other than ABO and RhD3. Sixty six 
percent of the alloantibodies identified in most of 
the reports were those of the Rhesus (Rh) and Kell 
systems in SCD5. Some studies identified 
alloantibodies of the Kidd and Duffy systems in 
addition to the Rh and Kell systems5. Factors 
implicated in RBC alloantibody formation include 
recipient sex and age, history of pregnancy, number 
and timing of blood transfusions, recipient clinical 
diagnosis and treatment, genetic factors related to 
antigenic response, and racial differences between 
donors and recipients6. 
Alloimmunization frequency varies among 
communities depending on various factors including 
ethnic, genetic differences and transfusion policies. 
To the best of our knowledge, sufficient data are not 
available in Turkey, therefore we aimed to 
investigate erythrocyte alloimmunization frequency 
and related factors in our region where SCD is 
common. 
MATERIAL AND METHODS 
Study Group and Data Collection 
This study was planned as a single center, cross- 
sectional and retrospective cohort study. A total of 
216 patients who had been followed up due to SCD 
[Hemoglobin (Hb) SS, Hb S-β thalassemia, Hb S-α 
thalassemia] in our center between 01 October 2011 
and 01 November 2015 were included in this study. 
A total of 160 patients whose detailed medical data 
could not been accessed and who did not have a 
definite diagnosis of SCD, who never underwent 
RBC transfusion, who underwent bone marrow 
transplantation and who died due to the other 
causes than SCD were excluded from the study. 
All procedures performed in studies involving 
human participants were in accordance with the 
ethical standards of the institutional and/or national 
research committee and with the 1975 Helsinki 
declaration and its later amendments or comparable 
ethical standards. This study was approved by 
Başkent University Institutional Review Board and 
Ethics Committee (project no: KA15/329).  
Definitions of Sickle Cell Disease Related 
Conditions 
Hydroxyurea regular use of 15 mg/kg/daily 
hydroxyurea for at least one month was considered. 
The patients who did not require medication due to 
painful conditions for 4 weeks were considered to 
be in steady state. Painful crisis was defined as the 
patient’s admission to hospital due to pain which 
was considered not to be related any other causes 
than SCD, intervention with parenteral NSAIDs, 
metamizol and narcotics1,2.  
Degree of crisis frequency was defined as rare if the 
patient experienced <3 painful crisis a year, frequent 
if the patient experienced ≥ 3 painful crisis a year. 
Nephropathy was defined as the presence of at least 
one of renal dysfunction as microalbuminuria and 
proteinuria, hyperecchogenity and/or thinning in 
renal cortex on ultrasonography, low creatinine 
clearance4. Pulmonary hypertension was defined as 
>25 mmHg mean resting pulmonary artery pressure 
or >30 mmHg following exercise and <15 mmHg 
pulmonary capillary pressure7. Avascular necrosis 
was defined as the presence of radiologically evident 
typical bone lesions4. 
Transfusion therapy was defined as Group 1 for the 
patients who had received less than 6 transfusions 
per year and who did not have the history of 
erythropheresis, Group 2 for the patients who had 
received 6 or more simple transfusion per year or 
who had undergone erythrocyte exchange. 
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Laboratory Studies 
For indirect antiglobulin screening, the sera were 
used by gel technology using commercial panel of 
cells “ID-DiaCell” (DiaMed ID, Micro Typing 
System, DiaMed, Cressier sur Morat, Switzerland) 
with polyspecific anti-human globulin (rabbit anti-
immunglobulin G and monoclonal anti-C3d). 
Patients were considered to be alloimmunized if 
antibodies to one or more erytrocyte antigens were 
identified. 
Statistical Analysis 
Patient characteristics were examined using 
descriptive statistics. Continuous variables were 
given as mean ± standard deviation (SD), and 
categorical variables were defined as percentage. 
Chi-square test and t-test were used to compare 
proportions and means for categorical and 
continuous variables, respectively.  For univariate 
analysis of possible associations between 
parameters, chi-square test or Fisher’s exact test was 
used for discrete variables. The variables which have 
significant p values (p<0.05) and marginal 
insignificant p values (p<0.1) in univariate analysis 
were included in multivariate analysis. All test 
significances were two-tailed. SPSS statistical 
software (SPSS 17.0 for Windows, Inc., Chicago, IL, 
USA) was used for all statistical calculations. 
RESULTS 
Of 216 SCD patients included in the study, 112 
(51.9%) were female and 104 (48.1%) were male 
with mean age of 33.9±9.7 years (18-64) (32.5±8.5 
years for males, 35.1±10.7 years for females). HbSS 
was detected in 158 (73.1%), HbSβ+ in 30 (13.9%) 
and HbSβ0 in 28 (13%) and 54.6% of the patients 
were detected to have been using hydroxyurea. 
When 216 patients were divided to groups according 
to transfusion therapy, 56 (25.9%) were in Group 1, 
160 (74.1%) were in group 2. Alloimmunization was 
detected in 67 (31.0%) out of 216 patients who 
underwent transfusion and autoantibody 
development was detected in 14 (20.9%) out of 
these 67 alloimmunized patients. Alloimmunization 
was detected in 17 (30.4%) out of 56 patients in 
Group 1 and in 50 (31.3%) out of 160 patients in 
Group 2. A statistically significant difference was 
not detected between groups with regard to 
alloimmunization ratios (p>0.05).  
Although Group 2 received more intense 
transfusion therapy, this was not found to lead to an 
additional risk for alloimmunization compared to 
Group 1 patients. Laboratory data of the patients 
are given in Table 1 and data of the patients about 
SCD complications are given in Table 2. A 
statistically significant difference was not detected 
between groups with regard to HbA, HbS, HbA2, 
Hb F, hemoglobin, hematocrit, white blood cell, 
platelet values, age, gender, hidroxyurea use, SCD 
complications (p>0.05). Our study revealed that 
neither SCD complications are a risk factor for 
alloimmunization nor alloimmunization increases 
mortality rates (Table 3).  
DISCUSSION 
Sickle cell anemias are inherited disorders of 
hemoglobin synthesis that result from the 
substitution of glutamic acid at the sixth position of 
its β-globin chain by valine (HbS)7. The HbS gene is 
found in high frequency in many parts of Africa, 
India, the Middle East, the Mediterranean area, and 
aparts of Turkey8. The primary manifestations of 
SCD are chronic hemolytic anemia and episodes of 
severe pain crises due to vasoocclusion9. Repeated 
vasooclusive crisis can affect multiple organ systems, 
and individuals with SCD have increased risks of 
stroke, renal dysfunction, pulmonary hypertension, 
retinal disease, and avascular necrosis9. RBC 
transfusions remain a cornerstone treatment for 
acute and chronic complications in SCD10. 
Approximately 90% of adults with SCD will have 
received at least one RBC transfusion9.Transfusion 
therapy facilitates blood and tissue oxygenation and 
reduces the propensity for sickling by diluting the 
host cells and temporarily suppresses the production 
of HbS-containing red cells11. Despite the beneficial 
effects of transfusion therapy in SCD, there are still 
adverse effects associated with transfusion that can 
lead to serious short and long-term complications 
including alloimmunization11. Prevalence of 
alloimmunization varies between 7-47% in SCD 
patients in literature3. . 
We detected alloimmunization prevalence as 31% in 
our study which was conducted due to the absence 
of data about alloimmunization in SCD patients in 
our region where SCD is prevalent. 
Alloimmunization was not found to be related with 
the other SCD-related complications like acute chest 
syndrome or stroke, consistently with the study of 
Telenet al4. 
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Table 1. Laboratory data of the patients 
 Total 
 
(N=216) 
Non-immunized 
patients 
(N=149) 
Alloimmunized 
patients 
(N=67) 
P value 
WBC (x103/mcL) 12.3±7.1 11.9±5.1 13.1±10.0 0.255 
Hgb (gr/dL) 8.7±1.7 8.8±1.6 8.5±1.9 0.260 
Hct (%) 25.6±5.4 25.8±5.4 25.0±5.6 0.284 
Plt (x103/mcL) 426±223 440±223 395±223 0.172 
Hb A (%) 8.2±13.4 9.4±14.9 5.6±8.8 0.078 
Hb A2 (%) 3.5±2.4 77.8±15.4 80.9±13.2 0.456 
Hb F (%) 8.8±10.1 8.6±10.2 9.3±10.0 0.669 
Hb S (%) 78.8±14.8 77.8±15.4 80.9±13.2 0.201 
WBC, white blood cell count; Hgb, hemoglobin; Hct, hematocrit; Plt, platelet  
Table 2. Data of the patients about SCD complications 
 Total 
 
(N=216) 
Non-immunized 
patients 
(N=149) 
Alloimmunized 
patients 
(N=67) 
Frequent Painful Crisis 29.6% 30.2% 28.4% 
History of Avascular Necrosis 5.6% 5.4% 6.0% 
History of Acute Chest Syndrome 9.7% 10.1% 9.0% 
History of Arterial Hypertension 8.4% 8.1% 9.0% 
Histroy of Heart Failure 4.6% 4.0% 6.1% 
History of Nephropathy 31.0% 31.5% 29.9% 
History of Pulmonary Hypertension 44.0% 46.3% 38.8% 
History of Cerebrovascular Disease 6.9% 6.7% 7.5% 
History of Pulmonary Thromboembolism 5.1% 4.7% 6.0% 
History of Deep Venous Thromboembolism 3.7% 4.0% 3.0% 
Death 7.4% 6.0% 10.4% 
Table 3. Comparison of groups and relative risk in alloimmunized patients. 
 Inter-group 
comparison 
Alloimmunized patients 
(N=67) 
 p RR (95% CI) 
Sex 0.901 0.971 (0.614-1.536) 
Hydroxyurea use 0.287 1.158 (0.875-1.533) 
Transfusion Requirement 0.765 0.926 (0.560-1.530) 
History of Erythropheresis 0.610 1.065 (0.833-1.362) 
Frequent Painful Crisis 0.784 1.065 (0.678-1.674) 
History of Avascular Necrosis 0.515 1.368 (0.518-3.613) 
History of Acute Chest Syndrome 0.799 1.124 (0.456-2.770) 
History of Arterial Hypertension 0.835 0.905 (0.355-2.310) 
History of Heart Failure 0.521 0.669 (0.195-2.292) 
History of Nephropathy 0.780 1.064 (0.688-1.646) 
History of Pulmonary Hypertension 0.388 1.157 (0.825-1.623) 
History of Cerebrovascular Disease 0.851 0.905 (0.322-2.546) 
History of Pulmonary Thromboembolism 0.702 0.792 (0.240-2.615) 
History of Deep Venous Thromboembolism 0.701 1.358 (0.281-6.555) 
Death 0.253 1.049 (0.958-1.150) 
 
Interestingly, the authors detected a relationship 
between alloimmunization and short life span in the 
same study, this possible association has not been 
previously studied4. We did not detect a relationship 
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between alloimmunization and mortality. 
Ugwu et al.11 reported that the prevalence of red cell 
alloantibody among multi-transfused patients with 
SCD was found to be 9.3% in Nigeria, and this 
finding further reaffirms that blood transfusion is 
associated with the development of alloantibodies11. 
Miller et al.12 reported alloimmunization prevalence 
as 14.4%.However mean age was lower in both 
studies (26 and 19.3 years, respectively) compared to 
our study (33.9 years) 
Elenga and Niel13 reported high ratio (16%) of 
alloimmunization development in French Guina. 
The authors explained that since blood cannot be 
collected locally, use of blood mostly from French 
Caucasian blood donors is causing alloimmunization 
in the Guianese population due to 
ethnic/geneticdifferences13. Natukunda et al.6 
reported that the rate of RBC alloimmunization in 
Ugandan SCD patients was 6.1%. The homogeneity 
between donors and SCD patients plus the low 
transfusion load may explain this low immunization 
frequency6. Chou et al.3 found alloimmunization 
prevalence as %58 among the patients who undergo 
chronic transfusion, 15% among the patients who 
undergo episodic transfusion. The authors suggest 
that altered Rh alleles in both patients and donors 
contributed to Rh alloimmunization3. Aly et al.13 
reported alloimmunization prevalence as 21.4% in 
42 Egyptian SCD patients. They concluded that low 
alloimmunization could probably be explained with 
the similarity in the ethnicity between patients and 
donors14. These studies emphasize the importance 
of ethnic/genetic differences between donors and 
recepients14. Therefore we also consider that this 
ethnic heterogeneity may be one of the factors 
responsible for high alloimmunization prevalence in 
our study population.  
Ameen et al.15 used two approaches in their study 
conducted with Kuwaiti Arab SCD patients. In the 
first approach (Group 1), the donor-recipient 
matching was random and limited to the 
conventional procedure for ensuring ABO and D 
antigen compability with nonleukoreduced blood 
until the patients develop RBC alloantibodies. For 
the second approach (Group 2), donor-recipient 
matching using poststorage-leukoreduced blood was 
limited to phenotype-matched blood for Rh (D, C, 
E, c, e) and Kl (partial phenotype matching)15. They 
found alloimmunization prevalence as 65.5% in 
Group 1, 23.6% in Group 215. They concluded that 
sex and blood transfusion protocol had significant 
effects on the rate of alloimmunization, consistently 
with the other studies and this study confirms the 
importance of selecting partial phenotype blood to 
prevent formation of antibodies related to the Rh 
systems15. We suggest that similar ratios of 
alloimmunization Group 1 (30.4%) and Group 2 
(31.3%) in our study is associated with our standard 
transfusion policy (leuko-depleted blood matched 
for antigens of the ABO, Rh and Kell systems and 
routine antibody screening for alloimmunized 
patients) on the contrary to the expectations that 
alloimmunization should be more frequent among 
the patients who received more transfusions. 
As discussed above, alloimmunization prevalence 
varies between populations in SCD patients. Many 
factors should be considered to minimize 
alloimmunization prevalence in this group of 
patients who need more frequent transfusions. The 
main factors which increase alloimmunization risk 
include increased patient age3,11, female gender2,14, 
history of pregnancy2,6, not applying 
leukoreduction15, use of long term stored blood 
products14,15, the number of transfused RBC 
units2,14, transfusion for acute vasoocclusive 
indications and elevated inflammatory status of the 
patients2, ethnic/genetic differences3,6,13.  
Our study has some limitations despite it yields 
significant data for our country. We could not 
sufficiently evaluate RBC transfusions that were 
performed out of our institution, a detailed 
stratification of the amount of transfusions could 
not be done and thereby the influence of this factor 
on alloimmunization could not be exactly evaluated 
and finally we could not provide alloantibody 
pattern as we could not obtain alloantibody 
screening data of all alloimmunized patients as this 
routine procedure was introduced in only recent 
years.  
In conclusion, high alloimmunization frequency 
found in our study suggests the insufficient 
adherence of alloimmunization-prevention policies 
in RBC transfusions performed except experienced 
institutions. Additionally, it is thought that the 
antigenic differences between recipients and donors 
could be effective depending on ethnic/genetic 
factors resulting from the heterogeneity of our 
population.  Therefore, alloimmunization may be 
reduced or prevented through performing extended 
red cell typing among SCD patients. So we suggest 
that the policies of Blood Transfusion Centers 
should be meticulously followed in order to prevent 
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red cell alloimmunization. Further studies are 
required to reveal the influence of ethnic and genetic 
factors on alloimmunization, to evaluate 
alloantibody pattern in our country. 
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